High incidence of adverse reactions to initial antiretroviral therapy in Brazil

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 4, 2006, Pages 495-505

  Menezes de Padua C A ^a   Cesar C C ^a   Bonolo, P F ^a   Acurcio, F A ^a   Guimaraes M D C ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Adverse reactions to antiretroviral therapy; Antiretroviral therapy; Medical records

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ACCURACY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALLERGY; ANEMIA; ARTICLE; BRAZIL; CLINICAL PROTOCOL; CONFIDENCE INTERVAL; CONSULTATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; FATIGUE; FEMALE; FEVER; HEADACHE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH CENTER; HEARTBURN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INSOMNIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; NAUSEA; NIGHTMARE; PATIENT COMPLIANCE; PATIENT REFERRAL; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SEX DIFFERENCE; STOMACH PAIN; T LYMPHOCYTE; TASTE DISORDER; VOMITING;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33645817702     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006000400010     Document Type: Article

References (25)

1. Sepkowitz KA (2001). AIDS - the first 20 years. New England Journal of Medicine, 344: 1764-1772.
2. Turpin JA (2003). The next generation of HIV/AIDS drugs: novel and developmental anti-HIV drugs and targets. Expert Review of Antiinfective Therapy, 1: 97-128.
3. Carr A & Cooper DA (2000). Adverse effects of antiretroviral therapy. Lancet, 356: 1423-1430.
4. Bonfanti P, Valsecchi L, Parazzini F et al. (2000). Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Journal of Acquired Immune Deficiency Syndromes, 23: 236-245.
5. Duran S, Spire B, Raffi F et al. (2001). Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials, 2: 38-45.
6. Lignani Jr L, Greco DB & Carneiro M (2001). Avaliaçāio da aderência aos anti-retrovirais em pacientes com infecçāo pelo HIV/Aids. Revista de Saúde Pública, 35: 495-501.
7. Dieleman JP, Jambroes M, Gyssens IC et al. (2002). Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS, 16: 737-745.
8. Mocroft A, Youle M, Moore A et al. (2001). Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS, 15: 185-194.
9. Ammassari A, Murri R, Pezzotti P et al. (2001). Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. Journal of Acquired Immune Deficiency Syndromes, 28: 445-449.
10. d'Arminio Monforte A, Lepri AC, Rezza G et al. (2000). Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS, 14: 499-507.
11. van Roon EN, Verzijl JM, Juttmann JR et al. (1999). Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 20: 290-294.
12. Lucas GM, Chaisson RE & Moore RD (1999). Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine, 131: 81-87.
13. Moore RD, Fortgang I, Keruly J et al. (1996). Adverse events from drug therapy for human immunodeficiency virus disease. American Journal of Medicine, 101: 34-40.
14. Bonfanti P, Ricci E, Landonio S et al. (2001). Predictors of protease inhibitor-associated adverse events. Biomedicine and Pharmacotherapy, 55: 321-323.
15. Fellay J, Boubaker K, Ledergerber B et al. (2001). Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet, 358: 1322-1327.
16. Currier JS, Spino C, Grimes J et al. (2000). Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. Journal of Acquired Immune Deficiency Syndromes, 24: 316-324.
17. Centers for Disease Control (1992). 1993 Revised classification system for HIV infection and expanded surveillance case definitions for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report, 41 (RR-1 7).
18. Pearson TF, Pittman DG, Longley JM et al. (1994). Factors associated with preventable adverse drug reactions. American Journal of Health-System Pharmacy, 51: 2268-2272.
19. Collett D (1994). Modeling Survival Data in Medical Research. Chapman & Hall, London, UK.
20. Brasil. Dados de AIDS no Brasil (Banco de dados). http://www.aids.gov.br. Accessed July 10, 2003.
21. Pfaffenbach G, Carvalho OM & Bergsten-Mendes G (2002). Reačões adversas a medicamentos como determinantes da admissão hospitalar. Revista da Associaçãio Méddica Brasileira, 48: 237-241.
22. Faragon JJ & Piliero PJ (2003). Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Reader, 13: 433-434, 437-441, 446-450.
23. Brasil. Recomendações para terapia anti-retroviral em adultos a adolescentes infectados pelo HIV - 2001. http://www.aids.gov.br. Accessed October 10, 2003.
24. Acurcio FA, César CC & Guimarães MDC (1998). Health care utilization and survival among patients with AIDS in Belo Horizonte, Minas Gerais, Brazil. Cadernas de Saúde Pública, 14: 811-820.
25. Justice AC, Rabeneck L, Hays RD et al. (1999). Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group. Journal of Acquired Immune Deficiency Syndromes, 21: 126-133.